×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
LON:SCLP

Scancell Share Forecast, Price & News

GBX 13.28
-0.47 (-3.42%)
(As of 06/27/2022 12:06 PM ET)
Add
Compare
Today's Range
13.28
13.75
50-Day Range
12.10
17.20
52-Week Range
10.50
23.90
Volume
257,408 shs
Average Volume
786,482 shs
Market Capitalization
£108.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive SCLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter.

SCLP Stock Forecast (MarketRank)

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
Scancell logo

About Scancell (LON:SCLP)

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

SCLP Stock News Headlines

Scancell treats first patient with Modi-1 cancer vaccine
Net Asset Value(s) - StreetInsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
25
Year Founded
N/A

Company Calendar

Last Earnings
1/31/2020
Today
6/27/2022

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 4.06 per share
Book Value
GBX 2.80 per share

Miscellaneous

Free Float
N/A
Market Cap
£108.26 million
Optionable
Not Optionable
Beta
N/A














Scancell Frequently Asked Questions

How has Scancell's stock performed in 2022?

Scancell's stock was trading at GBX 20 at the start of the year. Since then, SCLP stock has decreased by 33.6% and is now trading at GBX 13.28.
View the best growth stocks for 2022 here
.

How were Scancell's earnings last quarter?

Scancell Holdings plc (LON:SCLP) announced its quarterly earnings data on Friday, January, 31st. The company reported ($0.56) EPS for the quarter.
View Scancell's earnings history
.

Who are Scancell's key executives?

Scancell's management team includes the following people:
  • Prof. Lindy Gillian Durrant Ph.D., Founder, CEO, Chief Scientific Officer & Director
  • Dr. Richard Morley Goodfellow Ph.D., Interim Chief Bus. Officer & Non-Exec. Director
  • Dr. Sally Elizabeth Adams, Chief Devel. Officer & Director (Age 61, Pay $258.29k)
  • Mr. Keith Green, Director of Fin. & Admin. and Company Sec.
  • Dr. Samantha Paston Ph.D., Head of Translational Research
  • Dr. Adrian Parry Ph.D., Head of Manufacturing
  • Ms. Akua Asare, Head of Quality
  • Mr. Fayaz Master, Head of Clinical Operations

What other stocks do shareholders of Scancell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Petropavlovsk (POG), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Lloyds Banking Group (LYG), Aminex (AEX) and Sound Energy (SOU).

What is Scancell's stock symbol?

Scancell trades on the London Stock Exchange (LON) under the ticker symbol "SCLP."

How do I buy shares of Scancell?

Shares of SCLP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Scancell's stock price today?

One share of SCLP stock can currently be purchased for approximately GBX 13.28.

How much money does Scancell make?

Scancell (LON:SCLP) has a market capitalization of £108.26 million.

How many employees does Scancell have?

Scancell employs 25 workers across the globe.

How can I contact Scancell?

Scancell's mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The official website for Scancell is www.scancell.co.uk. The company can be reached via phone at +44-115-8231863.

This page (LON:SCLP) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.